Works by Jong Chul Won


Results: 48
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension

    Published in:
    Diabetes & Metabolism Journal, 2023, v. 47, n. 6, p. 808, doi. 10.4093/dmj.2022.0387
    By:
    • Jun Sung Moon;
    • Il Rae Park;
    • Hae Jin Kim;
    • Choon Hee Chung;
    • Kyu Chang Won;
    • Kyung Ah Han;
    • Cheol-Young Park;
    • Jong Chul Won;
    • Dong Jun Kim;
    • Gwan Pyo Koh;
    • Eun Sook Kim;
    • Jae Myung Yu;
    • Eun-Gyoung Hong;
    • Chang Beom Lee;
    • Kun-Ho Yoon
    Publication type:
    Article
    27
    28
    29

    The History of Insulin Therapy in Korea.

    Published in:
    Diabetes & Metabolism Journal, 2021, v. 45, n. 5, p. 623, doi. 10.4093/dmj.2021.0171
    By:
    • Jun Sung Moon;
    • Jong Chul Won;
    • Young Min Cho
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41

    Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin (AJU‐A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study

    Published in:
    Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 81, doi. 10.1111/dom.15985
    By:
    • Hong, Jun Hwa;
    • Kim, Myung Jin;
    • Min, Kyung Wan;
    • Won, Jong Chul;
    • Kim, Tae Nyun;
    • Lee, Byung‐Wan;
    • Kang, Jun Goo;
    • Kim, Jae Hyeon;
    • Park, Jung Hwan;
    • Ku, Bon Jeong;
    • Lee, Chang Beom;
    • Kim, Sang Yong;
    • Shon, Ho Sang;
    • Lee, Woo Je;
    • Park, Joong‐Yeol
    Publication type:
    Article
    42
    43
    44

    A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2188, doi. 10.1111/dom.15526
    By:
    • Lim, Soo;
    • Lee, Seung‐Hwan;
    • Min, Kyung‐Wan;
    • Lee, Chang Beom;
    • Kim, Sang Yong;
    • Yoo, Hye Jin;
    • Kim, Nan Hee;
    • Kim, Jae Hyeon;
    • Oh, Seungjoon;
    • Won, Jong Chul;
    • Kwon, Hyuk Sang;
    • Kim, Mi Kyung;
    • Park, Jung Hwan;
    • Jeong, In‐Kyung;
    • Kim, Sungrae
    Publication type:
    Article
    45

    Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
    By:
    • Kwak, Soo Heon;
    • Han, Kyung Ah;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Kim, EunSook;
    • Won, Jong Chul;
    • Kang, Jun Goo;
    • Chung, Choon Hee;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Won, Kyu Chang;
    • Kim, Sin Gon;
    • Cho, Seung Ah;
    • Cho, Bo Young;
    • Park, Kyong Soo
    Publication type:
    Article
    46
    47
    48